DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationMRCS

Non-coeliac gluten sensitivity and diagnostic pitfalls

Essential points for quick revision.

Synopsis

Evaluate symptoms attributed to gluten without missing coeliac disease, wheat allergy, inflammatory disease or nutritional harm; distinguish gluten from fructan and expectation effects; and use a supervised restriction-and-rechallenge strategy only after appropriate exclusion.

  • Non-coeliac gluten sensitivity describes reproducible intestinal or extra-intestinal symptoms related to wheat or gluten exposure after coeliac disease and wheat allergy are excluded; there is no validated diagnostic biomarker.
  • Do coeliac serology while gluten is still eaten and complete any required biopsy pathway before restriction, because diet change can normalise both.
  • Wheat contains fructans and other components, so improvement on a gluten-free diet does not prove gluten itself was the trigger.

Key red flags

Immediate wheat allergy

Rapid urticaria, angioedema, throat symptoms, wheeze, vomiting, hypotension or exercise-associated reaction after wheat suggests IgE-mediated allergy and can be life-threatening.

Investigation priorities

01
Coeliac serology with total IgAFirst step

Exclude coeliac disease while the person eats adequate gluten, using IgA tTG and assay-appropriate alternatives in IgA deficiency.

Management branches

ExcludeBefore gluten restriction

A patient attributes recurrent gastrointestinal or systemic symptoms to wheat or gluten.

  1. Document symptom pattern, current gluten exposure, family and autoimmune risk, immediate allergy features and organic red flags.
  2. Perform coeliac testing while gluten is consumed and refer positive or high-risk discordant cases; use the allergy pathway for rapid IgE-type reactions.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom